| Oncology |
Utilising the ability of rP-nanoTM to cross membrane and enhance delivery based on size (EPR effect) and natural interactions with membrane receptors present on cancer cells (e.g SPARC, gp60) |
| RNAi delivery |
Carrying RNAi molecules to the surface of target cells, promoting membrane transport and uptake into the cell cytoplasm |
| Oral delivery |
Having the potential to cross the intestinal wall in certain regions of the intestine based on size alone. |
| Topical delivery |
Enhancing the interaction of molecules with the surface of the skin, promoting transport and retention |
| Vaccines |
Producing nanoparticles made from antigen or antigen peptides linked to the surface of protein carrier nanoparticles. |
Many of these potential applications rely on the ability of the nanoparticles produced by the rP-nanoTM technology to cross membranes and enter cells and/or self-targeting properties of carrier proteins like albumin or transferrin.
| Example: uptake of recombinant human albumin nanoparticles into the cytoplasm of DHU-145 prostate tumour cells.
Cells were incubated with 10ug/ml nanoparticles labelled with fluorescent dye (green). Cell nucleus was then stained with DAPI (blue) and the cells fixed/subjected to fluorescent microscopy (green).
Fluorescent micrograph showing cellular uptake of fluorescent recombinant albumin nanoparticles (50nm mean size) into prostate tumour cells
|
